Skip to Content
MilliporeSigma
All Photos(1)

Documents

SCP0076

Sigma-Aldrich

Caspase 2 Inhibitor (ICH-1)

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C23H37N5O10
Molecular Weight:
543.57
UNSPSC Code:
12352200
NACRES:
NA.32

assay

≥95% (HPLC)

form

lyophilized

composition

Peptide Content, ≥80%

storage condition

protect from light

storage temp.

−20°C

Amino Acid Sequence

Ac-Val-Asp-Val-Ala-Asp-al

Application

Caspase 2 Inhibitor (Ac-VDVAD-CHO) is a non-selective (also inhibits caspase 3) but powerful inhibitor of caspase 2 used to study the role of caspase 2 in cell processes.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Michel C Maillard et al.
Bioorganic & medicinal chemistry, 19(19), 5833-5851 (2011-09-10)
Several caspases have been implicated in the pathogenesis of Huntington's disease (HD); however, existing caspase inhibitors lack the selectivity required to investigate the specific involvement of individual caspases in the neuronal cell death associated with HD. In order to explore
Bin Fang et al.
Journal of molecular biology, 360(3), 654-666 (2006-06-20)
The molecular basis for the substrate specificity of human caspase-3 has been investigated using peptide analog inhibitors and substrates that vary at the P2, P3, and P5 positions. Crystal structures were determined of caspase-3 complexes with the substrate analogs at
Ju Youn Kim et al.
Cell, 175(1), 133-145 (2018-09-18)
Nonalcoholic fatty liver disease (NAFLD) progresses to nonalcoholic steatohepatitis (NASH) in response to elevated endoplasmic reticulum (ER) stress. Whereas the onset of simple steatosis requires elevated de novo lipogenesis, progression to NASH is triggered by accumulation of hepatocyte-free cholesterol. We

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service